# Supplementary File 3 – supplementary results

## Prostate cancer model

### Deterministic results

**Supplementary Table 3. 1 Results for prostate cancer model: average number of patients entering the model, average estimates for referral patterns (%) for standard care and PinPoint test (both use cases) across 650 deterministic model replications, in the context of providers with high and average volume of referrals, sorted by performance scenarios**



**Supplementary Table 3. 2** **Results for prostate cancer model: average number of patients entering the model, average estimates for referral patterns (%) for standard care and PinPoint test (both use cases) across 650 deterministic model replications, in the context of providers with low volume of referrals, sorted by performance scenarios**



**Supplementary Table 3. 3 Full deterministic results for prostate cancer model for each testing strategy in the context high volume referrals sites, sorted by efficiency levels**

****



**Supplementary Table 3. 4 Full deterministic results for prostate cancer model for each testing strategy in the context average volume referrals sites, sorted by efficiency levels**





**Supplementary Table 3. 5 Full deterministic results for prostate cancer model for each testing strategy in the context low volume referrals sites, sorted by efficiency levels**





### Probabilistic results – 1200 PSA runs

## Bladder and kidney cancer model

### Deterministic results

**Supplementary Table 3. 6** **Results for bladder and kidney cancer model: average number of patients entering the model, average estimates for referral patterns (%) for standard care and PinPoint test (both use cases) across 650 deterministic model replications, in the context of providers with high and average volume of referrals, sorted by performance scenarios**

****

**Supplementary Table 3. 7** **Results for bladder and kidney model: average number of patients entering the model, average estimates for referral patterns (%) for standard care and PinPoint test (both use cases) across 650 deterministic model replications, in the context of providers with low volume of referrals, sorted by performance scenarios**

****

**Supplementary Table 3. 8 Full deterministic results for bladder and kidney cancer model for each testing strategy in the context of high volume referrals sites, sorted by efficiency levels**





**Supplementary Table 3. 9 Full deterministic results for bladder and kidney cancer model for each testing strategy in the context of average volume referrals sites, sorted by efficiency levels**





**Supplementary Table 3. 10 Full deterministic results for bladder and kidney cancer model for each testing strategy in the context of average volume referrals sites, sorted by efficiency levels**





### Probabilistic results – 1200 PSA runs